// App-Quantinova.ai

1407 : Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis

Researchers

Presenter

  • Janet Pope

Principal Investigators

  • Kei Ikeda

  • Xiang Zhang

  • Bochao Jia

  • Hong Zhang

  • Amanda Quebe

  • Yun-Fei Chen

  • Carol Gaich

  • Thorsten Holzkaemper

  • Anabela Cardoso

  • Anthony Sebba

Medical Centers

  • University of Oxford, Oxford, United Kingdom

  • Western Univeristy, London, ON, Canada

  • Chiba University Hospital, Chiba, Japan

  • Eli Lilly and Company, Indianapolis, IN

  • TechData Services, King of Prussia, PA

  • University of South Florida, Tampa, FL

Locations

  • United Kingdom

  • Canada

  • Japan

  • United States

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Baricitinib

  • Adalimumab

  • BARI

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved